J P Leombruno

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events
    J P Leombruno
    University of Toronto, Department of Pharmaceutical Sciences, Toronto, Ontario, Canada
    Ann Rheum Dis 68:1136-45. 2009
  2. ncbi Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis
    John Paul Leombruno
    Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada
    Pharmacoepidemiol Drug Saf 20:838-48. 2011

Detail Information

Publications2

  1. ncbi The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events
    J P Leombruno
    University of Toronto, Department of Pharmaceutical Sciences, Toronto, Ontario, Canada
    Ann Rheum Dis 68:1136-45. 2009
    ..To evaluate the safety of biological treatments for rheumatoid arthritis (RA) using results from randomised controlled trials (RCT)...
  2. ncbi Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis
    John Paul Leombruno
    Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada
    Pharmacoepidemiol Drug Saf 20:838-48. 2011
    ..These interventions account for most of the direct costs of the disease. We sought to explore the association between infliximab use and CD-related surgery and hospitalizations...